BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jun 27, 2005
 |  BioCentury  |  Product Development

Back to bradykinin

Almost a decade after Bradycor was terminated during Phase II development because of insufficient efficacy and fears of toxicity, Xytis Pharmaceuticals Ltd. is taking another shot at bradykinin inhibition. Xytis has in-licensed a small molecule bradykinin B2 receptor blocker, Anatibant, from Fournier Pharma. The deal gives Xytis its second and most advanced product.

Fournier granted Xytis an exclusive worldwide license to Anatibant (LF-16-0687MF) to treat traumatic brain injury (see BioCentury, June 20). The compound, which is delivered via subcutaneous injection, has completed some Phase I testing and has Orphan Drug designation in the U.S. and Europe, and Fast Track designation in the U.S.

Endogenous bradykinin is released at the site of injury after brain trauma, but it then migrates to healthy brain tissue, where it can cause brain swelling and ischemia. "It's the primary reason for secondary brain damage" in brain trauma patients, said Xytis CEO Werner Tschollar.

Bradycor was a peptide blocker of bradykinin. In October 1996,

Read the full 804 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >